Hong Kong Regulatory Update - July 2020

Published date14 July 2020
Subject MatterAcquisitions,Mergers,Medical Devices,Sanctions,Shareholders,Board of Directors,Publicly-Traded Companies,SFC,Biotechnology,Misappropriation,Enforcement Actions,Misleading Statements,Medical Research,False Statements,Internal Controls,HKEx,Hong Kong,Listing Rules,Hong Kong Stock Exchange,Hong Kong Securities and Futures Commission (HKSFC),Corporate Executives,Pharmaceutical Industry,Takeovers,Amended Rules,Censures,Secondary Listings,Weighted Voting Rights (WVR),Hang Seng Index (HSI),Hang Seng China Enterprises Index (HSCEI),Listing Applications
AuthorChristopher Betts,Paloma Wang,Anthony Pang
Law FirmSkadden, Arps, Slate, Meagher & Flom LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT